Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 4
- Registration Number
- NCT00511134
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Pharmacogenetics, Emotional Reactivity and Smoking
- Conditions
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 646
- Registration Number
- NCT00507728
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00449007
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Disease Management for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 750
- Registration Number
- NCT00440115
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 101
- Registration Number
- NCT00429169
- Locations
- 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States
Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 120
- Registration Number
- NCT00419731
- Locations
- 🇺🇸
Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota, United States
Craving, Binge Eating and Obesity
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 61
- Registration Number
- NCT00414167
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Dichotic Listening as a Predictor of Medication Response in Depression
- Conditions
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00404755
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 24
- Registration Number
- NCT00396669
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.